Who are Propranolol Oral Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ISOPROTERENOL, Norepinephrine Bitartrate In 5% Dextrose, Drug: latanoprost/timolol, spironolactone, beta-blockers,ecc, Ephedrine, continuous infusion, latanoprost/timolol fixed combination drops.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propranolol-oral-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Propranolol Oral Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Propranolol Oral Product (Propranolol Oral Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta-blocker. Area: Cardiovascular.

phase 3 beta-blocker beta-adrenergic receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Propranolol Oral Product (Propranolol Oral Product) — University Hospital, Toulouse. Propranolol is a beta-blocker that works by blocking the action of certain natural chemicals in your body, such as epinephrine, on the heart and blood vessels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Propranolol Oral Product TARGET	Propranolol Oral Product	University Hospital, Toulouse	phase 3	beta-blocker	beta-adrenergic receptors
ISOPROTERENOL	ISOPROTERENOL		marketed	Beta-adrenergic agonist	beta-adrenergic receptors	1956-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Drug: latanoprost/timolol	Drug: latanoprost/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog/beta-blocker combination	Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (β1 and β2)
spironolactone, beta-blockers,ecc	spironolactone, beta-blockers,ecc	University of Roma La Sapienza	marketed	Combination therapy: potassium-sparing diuretic + beta-adrenergic antagonist	Aldosterone receptor (mineralocorticoid receptor) and beta-adrenergic receptors (β1, β2)
Ephedrine, continuous infusion	Ephedrine, continuous infusion	University of Parma	marketed	Sympathomimetic amine	Alpha and beta-adrenergic receptors
latanoprost/timolol fixed combination drops	latanoprost/timolol fixed combination drops	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog / Beta-blocker combination	Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1 and β2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (beta-blocker class)

AstraZeneca · 1 drug in this class
University Hospital, Toulouse · 1 drug in this class
University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propranolol Oral Product — Competitive Intelligence Brief. https://druglandscape.com/ci/propranolol-oral-product. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab